282 related articles for article (PubMed ID: 15604992)
1. PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).
Shien T; Doihara H; Hara H; Takahashi H; Yoshitomi S; Taira N; Ishibe Y; Teramoto J; Aoe M; Shimizu N
Breast Cancer; 2004; 11(4):367-73. PubMed ID: 15604992
[TBL] [Abstract][Full Text] [Related]
2. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
[TBL] [Abstract][Full Text] [Related]
3. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.
Yang Z; Bagheri-Yarmand R; Wang RA; Adam L; Papadimitrakopoulou VV; Clayman GL; El-Naggar A; Lotan R; Barnes CJ; Hong WK; Kumar R
Clin Cancer Res; 2004 Jan; 10(2):658-67. PubMed ID: 14760089
[TBL] [Abstract][Full Text] [Related]
4. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
Barnes CJ; Bagheri-Yarmand R; Mandal M; Yang Z; Clayman GL; Hong WK; Kumar R
Mol Cancer Ther; 2003 Apr; 2(4):345-51. PubMed ID: 12700278
[TBL] [Abstract][Full Text] [Related]
5. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
6. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Normanno N; De Luca A; Maiello MR; Campiglio M; Napolitano M; Mancino M; Carotenuto A; Viglietto G; Menard S
J Cell Physiol; 2006 May; 207(2):420-7. PubMed ID: 16419029
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.
Bonaccorsi L; Marchiani S; Muratori M; Forti G; Baldi E
J Cancer Res Clin Oncol; 2004 Oct; 130(10):604-14. PubMed ID: 15258753
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
[TBL] [Abstract][Full Text] [Related]
9. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression.
Anderson NG; Ahmad T; Chan K; Dobson R; Bundred NJ
Int J Cancer; 2001 Dec; 94(6):774-82. PubMed ID: 11745477
[TBL] [Abstract][Full Text] [Related]
10. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH
J Natl Cancer Inst; 2003 Dec; 95(24):1825-33. PubMed ID: 14679152
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation.
Li J; Kleeff J; Giese N; Büchler MW; Korc M; Friess H
Int J Oncol; 2004 Jul; 25(1):203-10. PubMed ID: 15202007
[TBL] [Abstract][Full Text] [Related]
12. [Effect of gefitinib on the migration of triple-negative breast cancer cell line MDA-MB-231 cells].
Zhao HM; Zhang B; Li Y; Zhang L; Zhang F; Song YQ; Feng WH; Cao WF; Cao XC
Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):84-8. PubMed ID: 22780923
[TBL] [Abstract][Full Text] [Related]
13. Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib.
Matsuo M; Sakurai H; Ueno Y; Ohtani O; Saiki I
Cancer Sci; 2006 Feb; 97(2):155-62. PubMed ID: 16441427
[TBL] [Abstract][Full Text] [Related]
14. Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors.
Albitar L; Laidler LL; Abdallah R; Leslie KK
Mol Cancer Ther; 2005 Dec; 4(12):1891-9. PubMed ID: 16373704
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2.
Nutt JE; Lazarowicz HP; Mellon JK; Lunec J
Br J Cancer; 2004 Apr; 90(8):1679-85. PubMed ID: 15083203
[TBL] [Abstract][Full Text] [Related]
16. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
Normanno N; Campiglio M; De LA; Somenzi G; Maiello M; Ciardiello F; Gianni L; Salomon DS; Menard S
Ann Oncol; 2002 Jan; 13(1):65-72. PubMed ID: 11863114
[TBL] [Abstract][Full Text] [Related]
17. Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition.
Agelaki S; Spiliotaki M; Markomanolaki H; Kallergi G; Mavroudis D; Georgoulias V; Stournaras C
Cancer Biol Ther; 2009 Aug; 8(15):1470-7. PubMed ID: 19483462
[TBL] [Abstract][Full Text] [Related]
18. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
19. Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ('Iressa', ZD1839).
Hirata A; Uehara H; Izumi K; Naito S; Kuwano M; Ono M
Cancer Sci; 2004 Jul; 95(7):614-8. PubMed ID: 15245600
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.
Jones HE; Goddard L; Gee JM; Hiscox S; Rubini M; Barrow D; Knowlden JM; Williams S; Wakeling AE; Nicholson RI
Endocr Relat Cancer; 2004 Dec; 11(4):793-814. PubMed ID: 15613453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
